Prometheus Biosciences Stock Current Asset
| RXDXDelisted Stock | USD 199.92 0.24 0.12% |
Prometheus Biosciences fundamentals help investors to digest information that contributes to Prometheus Biosciences' financial success or failures. It also enables traders to predict the movement of Prometheus Stock. The fundamental analysis module provides a way to measure Prometheus Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Prometheus Biosciences stock.
Prometheus |
Prometheus Biosciences Company Current Asset Analysis
Prometheus Biosciences' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Prometheus Biosciences Current Asset | 135.99 M |
Most of Prometheus Biosciences' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prometheus Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, Prometheus Biosciences has a Current Asset of 135.99 M. This is 93.68% lower than that of the Biotechnology sector and 87.18% lower than that of the Health Care industry. The current asset for all United States stocks is 98.54% higher than that of the company.
Prometheus Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prometheus Biosciences' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prometheus Biosciences could also be used in its relative valuation, which is a method of valuing Prometheus Biosciences by comparing valuation metrics of similar companies.Prometheus Biosciences is currently under evaluation in current asset category among its peers.
Prometheus Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (40.65) % | |||
| Current Valuation | 4.39 B | |||
| Shares Outstanding | 47.81 M | |||
| Shares Owned By Insiders | 16.61 % | |||
| Shares Owned By Institutions | 81.01 % | |||
| Number Of Shares Shorted | 4.68 M | |||
| Price To Earning | (5.66) X | |||
| Price To Book | 19.88 X | |||
| Price To Sales | 627.82 X | |||
| Revenue | 6.81 M | |||
| Gross Profit | (106.04 M) | |||
| EBITDA | (145.78 M) | |||
| Net Income | (141.75 M) | |||
| Cash And Equivalents | 95.96 M | |||
| Cash Per Share | 2.35 X | |||
| Total Debt | 14.76 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 13.32 X | |||
| Book Value Per Share | 14.62 X | |||
| Cash Flow From Operations | (123.25 M) | |||
| Short Ratio | 3.97 X | |||
| Earnings Per Share | (3.54) X | |||
| Target Price | 190.0 | |||
| Number Of Employees | 97 | |||
| Beta | -0.49 | |||
| Market Capitalization | 9.56 B | |||
| Total Asset | 740.77 M | |||
| Retained Earnings | (331.09 M) | |||
| Working Capital | 685.33 M | |||
| Current Asset | 135.99 M | |||
| Current Liabilities | 24.54 M | |||
| Net Asset | 740.77 M |
About Prometheus Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prometheus Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prometheus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prometheus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |